NEW YORK — Australian diagnostics firm Genetic Technologies said on Thursday that it has signed an agreement to commercialize its COVID-19 risk test in the US with Infinity Biologix.
Genetic Technologies' test is designed to assess the risk of an individual developing severe disease if they contract COVID-19 based on a combination of genetic and clinical factors.